Data from FDA - Curated by EPG Health - Last updated 20 December 2016

Indication(s)

INDICATIONS AND USAGE Technetium Tc 99m Pyrophosphate Injection is a bone imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction.

Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection is a blood pool imaging agent which may be used for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding.

When reconstituted with sterile non-pyrogenic isotonic saline and administered intravenously 30 minutes prior to the intravenous administration of Sodium Pertechnetate Tc 99m Injection, approximately 76 % of the injected radioactivity remains in the blood pool.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

ESICM LIVES Highlights

ESICM LIVES Highlights

ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.

Load more

Related Content

Advisory information

contraindications
CONTRAINDICATIONS None known.
Special warnings and precautions

PRECAUTIONS General The lyophilized contents of the Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection reaction vial are to be administered to the patient only as an intravenous solution (see Procedures for Reconstitution).

Any Sodium Pertechnetate Tc 99m solution which contains an oxidizing agent is not suitable for use with Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection.

When reconstituted with Sodium Pertechnetate Tc 99m, Technetium Tc 99m Pyrophosphate Injection must be used within 6 hours.

Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection may also be reconstituted with sterile, non-pyrogenic isotonic saline containing no preservatives and injected intravenously prior to the administration of Sodium Pertechnetate Tc 99m Injection.

Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection contains no preservatives.

Vials are sealed under nitrogen: air or oxygen is harmful to the contents of the vials and the vials should not be vented.

The components of the Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection are supplied sterile and non-pyrogenic.

Aseptic procedures normally employed in making additions and withdrawals for sterile, non-pyrogenic containers should be used during addition of the Sodium Pertechnetate Tc 99m Injection and the withdrawal of doses for patient administration.

Shielding should be utilized when preparing Technetium Tc 99m Pyrophosphate Injection.

Technetium Tc 99m Pyrophosphate Injection as well as other radioactive drugs must be handled with care, and appropriate safety measures should be used to minimize radiation exposure to the patients and clinical personnel consistent with proper patient management.

The solution should not be used if cloudy, discolored, or found to contain particulate matter.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

No special handling is required for the non-radioactive drug product.

Bone Imaging Both prior to and following Technetium Tc 99m Pyrophosphate Injection administration, if not contraindicated for the patient 's cardiac condition, patients should be encouraged to drink fluids.

Patients should void as often as possible after the Technetium Tc 99m Pyrophosphate Injection to minimize background interference and unnecessary radiation exposure from accumulation in the bladder.

Cardiac Imaging Patient 's cardiac condition should be stable before beginning the cardiac imaging procedure.

Interference from chest wall lesions such as breast tumors and healing rib fractures can be minimized by employing the three recommended projections.

(See DOSAGE AND ADMINISTRATION).

False-positive and false-negative myocardial scans may occur; therefore, the diagnosis of acute myocardial infarction depends on the overall assessment of laboratory and clinical findings.

Blood Pool Imaging The non-radioactive reconstituted agent should be injected by direct venipuncture.

Heparinized catheter systems should be avoided, as interference with red blood cell tagging will result.

Cardiac pool imaging should be initiated 15 to 30 minutes after the administration of Sodium Pertechnetate Tc 99m Injection.

The imaging of gastrointestinal bleeding is dependent on such factors as the region of imaging, rate and volume of the bleed, efficacy of the labeling of the red blood cells and timeliness of imaging.

Due to these factors, images should be taken sequentially over a period of time until a positive image is obtained or clinical conditions warrant the discontinuance of the procedure.

The period of time for collecting the images may range up to 36 hours.

Technetium Tc 99m Pyrophosphate Injection and the non-radioactive reconstituted Kit for the Preparation of

Technetium

Tc 99m Pyrophosphate Injection should be formulated within six (6) hours prior to clinical use.

Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate carcinogenic potential or whether Technetium Tc 99m Pyrophosphate Injection affects fertility in males or females.

Mutagenesis studies have not been conducted.

Pregnancy Category C Animal reproduction and teratogenicity studies have not been conducted with Technetium Tc 99m Pyrophosphate Injection.

It is also not known whether Technetium Tc 99 Pyrophosphate Injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.

Technetium Tc 99m Pyrophosphate Injection should be given to a pregnant woman only if clearly needed.

Ideally, examinations using radiopharmaceuticals, especially those elective in nature, to a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.

Nursing mothers Technetium Tc 99m Pyrophosphate Injection is excreted in human milk during lactation, therefore, formula feeding should be substituted for breast feeding.

Pediatric use Safety and effectiveness in pediatric patients have not been established.

Geriatric use Clinical studies of the Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Adverse reactions
ADVERSE REACTIONS Some hypersensitivity reactions have been associated with pyrophosphate use.

Usage information

Dosing and administration

DOSAGE AND ADMINISTRATION After preparation with oxidant-free Sodium Pertechnetate Tc 99m Injection, the suggested dose range of Technetium Tc 99m Pyrophosphate Injection in the average ADULT patient (70 kg) is: Bone Imaging - 185-555 megabecquerels (5-15 mCi) Cardiac Imaging - 370-555 megabecquerels (10-15 mCi) The suggested dose range of the non-radioactive reconstituted Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection in the average ADULT patient (70 kg) is: Blood Imaging - Administer not less that one-third nor more than the total contents of one vial [555-740 megabecquerels (15-20mCi) of Pertechnetate Tc 99m Injection].

Bone and Cardiac Imaging Technetium Tc 99m Pyrophosphate Injection is injected intravenously over a 10 to 20 second period.

For optimal results, bone imaging should be done 1 to 6 hours following administration.

Cardiac imaging should be done 30 to 90 minutes following administration.

The acute myocardial infarct can be visualized from 24 hours to 6 days following onset of symptoms, with maximum localization at 48 to 72 hours.

Cardiac imaging should be done with a gamma scintillation camera.

It is recommended that images be made of the anterior, left anterior oblique and left lateral projections.

Blood Pool Imaging Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection may be reconstituted with sterile, non-pyrogenic isotonic saline containing no preservatives.

Administer not less than one-third nor more than the total contents of one vial 30 minutes prior to the intravenous administration of 555 to 740 megabecquerels (15-20 mCi) Sodium Pertechnetate Tc 99m Injection.

The non-radioactive reconstituted Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection should be injected by direct venipuncture.

Heparinized catheter systems should be avoided.

Cardiac imaging should be done 10 to 30 minutes following the administration of Sodium Pertechnetate Tc 99m Injection utilizing a scintillation camera interfaced to an electrocardiographic gating device.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Radiation Dosimetry Bone and Cardiac Imaging The effective half-life was assumed to be the physical half-life for all calculated values.

The estimated radiation absorbed doses to an average ADULT patient (70 kg) from an intravenous injection of a maximum of 555 megabecquerels (15 mCi) of Technetium Tc 99m Pyrophosphate Injection are shown in Table 4.

TABLE 4: Estimated Absorbed Radiation Doses Bone and Cardiac Imaging * Technetium Tc 99m Pyrophosphate Injection Target Organ mGy/555 MBq rads/15 mCi Total Body 1.8 0.18 Kidneys 3.6 0.36 Red Marrow 3.5 0.35 Bone Surfaces 21.1 2.11 Bladder Wall 13.3 1.33 Testes 1.4 0.14 Ovaries 2.1 0.21 Effective Dose

Equivalent 3.3 mSv 0.33 rem * Based on the model in MIRD Dose Estimate Report No. 13 (J Nucl Med 30:1117 - 1122, 1989).

Estimate calculated using phantoms of Cristy & Eckerman (Report ORNL/TM-8381/V1 & V7).

Bone and marrow model of Eckerman (Aspects of dosimetry of radionuclides within the skeleton with particular emphasis on the active marrow.

In Fourth International Radiopharmaceutical Dosimetry Symposium; A.T. Schlafke-Stelson and E.E. Watson eds.

CONF-851113, Oak Ridge Associated Universities, Oak Ridge, TN 37831, 1986.

pp 514-534.

) used.

The effective dose equivalent is a quantity which may be suitable for comparing risks of different procedures in nuclear medicine, radiology, and other applications involving ionizing radiation, but should not be construed to give information about risks to individual patients and should not be applied to situations involving radiation therapy.

Blood Pool Imaging The estimated absorbed radiation doses to an average adult patient (70 kg) from an intravenous injection of 740 megabecquerels (20 mCi) of Sodium Pertechnetate Tc 99m Injection, 30 minutes after the intravenous administration of the non-radioactive reconstituted Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection are shown in Table 5.

TABLE 5: Estimated Absorbed Radiation Doses Blood Pool Imaginga Sodium Pertechnetate Tc 99m 30 min. Post Injection with Pyrophosphate Target Organ mGy/740 MBq rads/20 mCi Total Body 3.2 0.32 Spleen 3.6 0.36 Bladder Wallb 24.0 2.40 Testes 2.4 0.24 Ovaries 4.6 0.46 Blood 10.4 1.04 Red Marrow 4.4 0.44 a Assume 75 % of the Sodium Pertechnetate Tc 99m labels red blood cells and the other 25 % remains as pertechnetate.

Method of calculation: MIRD Dose Estimate Report No. 8, J Nucl Med.

17: 74-77, 1976.

b If 25 % excreted with 1 hour Tb

Pregnancy and lactation
Nursing mothers Technetium Tc 99m Pyrophosphate Injection is excreted in human milk during lactation, therefore, formula feeding should be substituted for breast feeding.

More information

Category Value
Authorisation number NDA019039
Agency product number 5L76I61H2B
Orphan designation No
Product NDC 45567-0060
Date Last Revised 06-02-2014
Type HUMAN PRESCRIPTION DRUG
Marketing authorisation holder Pharmalucence, Inc.